Treatment with anakinra appears beneficial to children with secondary haemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS), especially when administered early in the disease course and to those who have an underlying rheumatic disease, as shown in a study.
Use of ustekinumab in the treatment of systemic lupus erythematosus leads to significant improvements in many of the efficacy indices evaluated, with lower risk of flares and sustained response rates, when compared with placebo, according to 1-year data from a phase II trial.
Components of the renin-angiotensin system (RAS), such as renin, angiotensin-converting enzyme (ACE), matrix metalloproteinase-13 (MMP-13) and vascular endothelial growth factor (VEGF), are more elevated in the synovial fluid of patients with rheumatoid arthritis (RA) than with osteoarthritis (OA), a recent study has shown.
Use of active transcutaneous electrical nerve stimulation (TENS) in fibromyalgia (FM) patients receiving treatment results in a favourable reduction in movement-evoked pain, according to the results of a trial.
Tumour necrosis factor-α (TNF-α) inhibitors infliximab, golimumab and adalimumab are as effective as novel biologic agents ustekinumab, secukinumab and ixekizumab in the treatment of dactylitis and enthesitis, results of a systematic review and meta-analysis have shown.
Prevention of glucocorticoid-induced osteoporosis (GIOP) and postmenopausal osteoporosis (PMOP) remains inadequate in patients with rheumatoid arthritis (RA), as shown in a study that evaluated the implementation of the 2003 and 2014 French guidelines on the prevention and treatment of GIOP and the 2012 update of the French guidelines for the treatment of PMOP.
The new selective cathepsin K inhibitor MIV-711 does not perform better than placebo in easing osteoarthritic pain, a study has shown. However, it substantially decreases bone and cartilage progression with a reassuring safety profile.